Figure 3
From: Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
PDX grafting as prognosis determinant and PDXs growth characteristics. (A) 5-years OS of all patients involved in PDX platform establishment. 5-years OS of patients from whom PDX was successfully established (grafted) was significantly lower than OS of patients whose tumour sample did not give rise to a PDX (not grafted) (Log-rank test p = 0.0008). (B) 5-years OS was lower for stage III/IV patients than stage I/II patients (20%; 95% CI, 10–36% and 73%; 95% CI, 56–85%, respectively). Interestingly, stage III/IV patients with grafted PDX still maintained a significantly lower OS than not grafted (Log-rank test p = 0.0027) whereas stage I/II patients with grafted PDXs showed only a slight tendency towards a lower than not grafted 5-years OS. (C) Average time to transplantation (from P3 to P10, TTP3–P7) for each PDX. ADC = Adenocarcinoma, SCC = Squamous Cell Carcinoma. (D) ADC could be divided in two distinct groups based on their growth characteristics, fgADC = fast growing ADC with TT < 44.95 days and sgADC = slow growing adenocarcinomas with TT > 44.95 days (44.95 days corresponded to the average GT of all PDXs). (E) Patient’s DFS and PDXs grafting time (GT, time a model needs to stabilize in mouse and reach P3) were not linearly correlated (n = 38, p = 0.678, r2 = 0.005), and for 23 PDXs DFS was higher than GT.
